Navigation Links
Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
Date:11/12/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Nov. 12 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced positive final results from its pilot GHRH Phase II study. Within only 4 weeks of treatment, Akela GHRH induced a highly significant stimulation of endogenous growth hormone (GH) secretion and a marked increase of circulating insulin-like growth factor (IGF-1) as compared to placebo in patients with chronic kidney disease. These endocrine effects were associated with a significant increase in Fat Free Mass (FFM), and concomitant reduction in Fat Mass (FM) when measured by DEXA scan and bioelectrical impedance (BIA). As we reported in July 2007, the study did not reveal significant changes between treatment groups in total body protein turnover. Total body protein turnover, as measured by 13C leucine kinetics, was normal in both treatment groups already at baseline, most probably reflecting adaptative changes of metabolic balance in the chronic disease state.

ABOUT THE STUDY:

The study was conducted at 3 European sites. It was designed to evaluate the clinical potential of GHRH analogue (AKL-0707) administration in improving body composition, nutritional and metabolic parameters in malnourished patients with stage IV or pre-dialytic stage V chronic kidney disease (CKD). Malnutrition was defined by either serum albumin <40 g/l, body mass index (BMI) <23, or a greater than 5% loss of body weight in the last 6 months.

Twenty-eight patients were randomized to either GHRH analogue subcutaneously (sc.) (13 patients) or placebo sc. (15 patients). Twenty-six subjects completed the study as planned. The mean age was 61.8 and 63.4 in the GHRH analogue and placebo groups, respectively. The treatment was administered twice daily (AM & PM) for
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Akela Pharma reports results for third quarter of fiscal 2007
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... disease, is caused by the bacterium Mycobacterium ... is a legal obligation to report the disease. ... and wasting among affected animals. The disease can ... animals produce less milk, exhibit fertility problems and ... udder inflammation. , To date there has ...
(Date:9/19/2014)... Lifeinsuranceprices.info has released a new blog ... insurance quotes online. , Clients who smoke or ... life insurance quotes from multiple providers on a single ... , Smoking will always influence life insurance prices, ... 50% more for life coverage and if they have ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development ... for the Xaverian Brothers. The new site aligns the Catholic ... edify one another through a life of Gospel witness lived ... manifest God’s care and compassionate love to the people of ... using a responsive web design, which allows users to easily ...
(Date:9/19/2014)... September 19, 2014 2014 Market ... a professional and in-depth research report on Kinesio ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:9/19/2014)... Outsourcing services provider Profit By RPO has ... conglomerate to provide HR outsourcing services in India. , " ... partner and will act as a talent acquisition and transformation ... 120 personnel across 3 locations in India in the next ... is a significant win for us and we are delighted ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:Smokers Can Compare Term Life Insurance Quotes At Lifeinsuranceprices.info! 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 3Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2
... Year, LIVINGSTON, N.J., Dec. 7 MM2 ... its wholly-owned subsidiary,Genotec Nutritionals, Inc., a New York ... distribution of its branded products and,through custom formulations ... strategic venture to manufacture sofgel capsules in Zhongsan,City, ...
... heart disease, ... Gary Stanton., MELBOURNE, Fla., Dec. 7 Heart Savior, (http://www.heartsavior.com ... one Natural product. Lowering unhealthy cholesterol levels is a good,start, but ... in the arteries and the heart muscle itself. The formulators of,Heart ...
... Conn., Dec. 7 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ... (PNH), as well as to Soliris(R),(eculizumab), a treatment for ... Society of Hematology Meeting, December 8 - 11 in ... a poster session on red,cell regulation and disorders of ...
... Dec. 6 Inverness Medical,Innovations, Inc. (Amex: ... rapid,diagnostic products for the consumer and professional markets, ... RBC Capital Markets Healthcare,Conference being held December 12, ... Ron Zwanziger, Chief Executive Officer, and Jon Russell, ...
... Effort is part of the ,Holidays at Mariners Inn - ... Friday, December 7, 2007 at 5:30 p.m. ,These men ... Dec. 6 Homeless men from the,Mariners Inn shelter and ... needy families this holiday season. The men will kick off,their ...
... The American Dietetic,Association welcomes and supports changes announced ... to the nation,s Special Supplemental,Nutrition Program for Women, ... the foods included in the WIC program more ... young children., "These changes are the most ...
Cached Medicine News:Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 2Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 3Health News:New Health Corp. Introduces Heart Savior(TM), the Ultimate Natural Heart Health Product 2Health News:Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting 2Health News:Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007 2Health News:Detroit Homeless Men Adopt Local Families for Christmas 2Health News:American Dietetic Association Supports USDA's New WIC Food Packages 2
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... N.J., April 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... presented at the European League Against Rheumatism (EULAR) 2011 Annual ... 28 in London, United Kingdom, and will feature the abstracts ... The first scheduled oral presentation and the poster session will ...
... April 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ... Healthcare Conference being held May 2 to 4, 2011 at ... America Merrill Lynch Healthcare Conference being held May 10 to ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3
Malaria Pf. Assay Range...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: